Bioextrax: An exciting summer ahead - VH Corp
Tämä on kolmannen osapuolen analyysi, eikä välttämättä vastaa Inderesin näkemystä tai arvoja
* Expecting agreements to materialise
* Costs still in check
* We keep our fair value to SEK 4.23 per share
In the Q1 report 2025, CEO Edvard Hall updated on current projects. Before the
Q2 report in August, we expect some of the collaborations to advance to the
next phase. Costs were in line, and we keep our fair value of SEK 4.23 per
share.
* Costs still in check
* We keep our fair value to SEK 4.23 per share
In the Q1 report 2025, CEO Edvard Hall updated on current projects. Before the
Q2 report in August, we expect some of the collaborations to advance to the
next phase. Costs were in line, and we keep our fair value of SEK 4.23 per
share.